Status:
COMPLETED
Beta-2 Polymorphisms and Beta Receptor Selectivity
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
We hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients with heart failure treated with either a b1-selective or a b-nonselective agent. b-2 polymorphisms may contrib...
Eligibility Criteria
Inclusion
- systolic dysfunction with ejection fraction ≤40%
- symptomatic heart failure class 2-3
- \>18 years of age
- optimal medical therapy of HF excluding the use of any beta-blockers within the previous 30 days of the study
Exclusion
- active myocarditis
- hemodynamically significant valvular heart disease
- hypertrophic cardiomyopathy
- contra-indications to beta-blockers
- concomitant use of beta-agonists
- beta-antagonist or anti-arrhythmics
- unstable angina
- myocardial infarction or bypass surgery within 3 months
- significant renal insufficiency \[creatinine \>2.5 mg/dL\], liver disease, or anemia
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00214318
Start Date
January 1 2005
End Date
February 1 2007
Last Update
October 8 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792